Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Temporomandibular Disorders: "Occlusion" Matters!

de Kanter RJAM, Battistuzzi PGFCM, Truin GJ.

Pain Res Manag. 2018 May 15;2018:8746858. doi: 10.1155/2018/8746858. eCollection 2018. Review.

2.

S1P1 Modulator-Induced G αi Signaling and β-Arrestin Recruitment Are Both Necessary to Induce Rapid and Efficient Reduction of Blood Lymphocyte Count In Vivo.

Birker-Robaczewska M, Bolli M, Rey M, de Kanter R, Kohl C, Lescop C, Boucher M, Poirey S, Steiner B, Nayler O.

Mol Pharmacol. 2018 Feb;93(2):109-118. doi: 10.1124/mol.117.109140. Epub 2017 Dec 4.

PMID:
29203519
3.

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.

Bezençon O, Heidmann B, Siegrist R, Stamm S, Richard S, Pozzi D, Corminboeuf O, Roch C, Kessler M, Ertel EA, Reymond I, Pfeifer T, de Kanter R, Toeroek-Schafroth M, Moccia LG, Mawet J, Moon R, Rey M, Capeleto B, Fournier E.

J Med Chem. 2017 Dec 14;60(23):9769-9789. doi: 10.1021/acs.jmedchem.7b01236. Epub 2017 Nov 20.

PMID:
29116786
4.

Milestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies.

Bezençon O, Siegrist R, Heidmann B, Pozzi D, Stamm S, Remeň L, Richard S, Simons L, Gaston R, Downing D, Grisostomi C, Roch C, Kessler M, Gatfield J, Moon R, Pfeifer T, Mosbacher J, Reymond I, Ertel EA, de Kanter R, Capeleto B, Fournier E, Rey M, Moccia L, Toeroek-Schafroth M, Roscher R, Schindelholz B.

Chimia (Aarau). 2017 Oct 25;71(10):722-729. doi: 10.2533/chimia.2017.722.

PMID:
29070417
5.

The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.

Gnerre C, Segrestaa J, Seeland S, Äänismaa P, Pfeifer T, Delahaye S, de Kanter R, Ichikawa T, Yamada T, Treiber A.

Xenobiotica. 2018 Jul;48(7):704-719. doi: 10.1080/00498254.2017.1357088. Epub 2017 Aug 30.

PMID:
28737453
6.

The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468.

Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, Schindelholz B, Muehlan C, van Gerven J, Jenck F.

J Pharmacol Exp Ther. 2017 Sep;362(3):489-503. doi: 10.1124/jpet.117.241596. Epub 2017 Jun 29.

7.

Letter to the Editor, Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.

de Kanter R, Kohl C.

Biopharm Drug Dispos. 2017 Oct;38(7):443-444. doi: 10.1002/bdd.2079. Epub 2017 Jun 28. No abstract available.

PMID:
28656708
8.

Correction to Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Siegrist R, Pozzi D, Jacob G, Torrisi C, Colas K, Braibant B, Mawet J, Pfeifer T, de Kanter R, Roch C, Kessler M, Moon R, Corminboeuf O, Bezençon O.

J Med Chem. 2017 Mar 9;60(5):2163. doi: 10.1021/acs.jmedchem.7b00219. Epub 2017 Feb 24. No abstract available.

PMID:
28234473
9.

Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Siegrist R, Pozzi D, Jacob G, Torrisi C, Colas K, Braibant B, Mawet J, Pfeifer T, de Kanter R, Roch C, Kessler M, Corminboeuf O, Bezençon O.

J Med Chem. 2016 Dec 8;59(23):10661-10675. Epub 2016 Nov 23.

PMID:
27933950
10.

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.

Le Bihan A, de Kanter R, Angulo-Barturen I, Binkert C, Boss C, Brun R, Brunner R, Buchmann S, Burrows J, Dechering KJ, Delves M, Ewerling S, Ferrer S, Fischli C, Gamo-Benito FJ, Gnädig NF, Heidmann B, Jiménez-Díaz MB, Leroy D, Martínez MS, Meyer S, Moehrle JJ, Ng CL, Noviyanti R, Ruecker A, Sanz LM, Sauerwein RW, Scheurer C, Schleiferboeck S, Sinden R, Snyder C, Straimer J, Wirjanata G, Marfurt J, Price RN, Weller T, Fischli W, Fidock DA, Clozel M, Wittlin S.

PLoS Med. 2016 Oct 4;13(10):e1002138. doi: 10.1371/journal.pmed.1002138. eCollection 2016 Oct.

11.

Novel S1P1 receptor agonists - Part 4: Alkylaminomethyl substituted aryl head groups.

Lescop C, Müller C, Mathys B, Birker M, de Kanter R, Kohl C, Hess P, Nayler O, Rey M, Sieber P, Steiner B, Weller T, Bolli MH.

Eur J Med Chem. 2016 Jun 30;116:222-238. doi: 10.1016/j.ejmech.2016.03.048. Epub 2016 Mar 23.

PMID:
27061986
12.

Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.

Brian W, Tremaine LM, Arefayene M, de Kanter R, Evers R, Guo Y, Kalabus J, Lin W, Loi CM, Xiao G.

Pharmacogenomics. 2016 Apr;17(6):615-31. doi: 10.2217/pgs.16.9. Epub 2016 Apr 5. Review.

PMID:
27045656
13.

Novel S1P1 receptor agonists - Part 5: From amino-to alkoxy-pyridines.

Bolli MH, Lescop C, Birker M, de Kanter R, Hess P, Kohl C, Nayler O, Rey M, Sieber P, Velker J, Weller T, Steiner B.

Eur J Med Chem. 2016 Jun 10;115:326-41. doi: 10.1016/j.ejmech.2016.03.020. Epub 2016 Mar 12.

PMID:
27027817
14.

[Dissertations 25 years after date 45. Prevalence and etiology of craniomandibular dysfunction in the Netherlands].

de Kanter RJ.

Ned Tijdschr Tandheelkd. 2016 Mar;123(3):138-44. doi: 10.5177/ntvt.2016.03.15218. Review. Dutch.

PMID:
26973986
15.

Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.

de Kanter R, Sidharta PN, Delahaye S, Gnerre C, Segrestaa J, Buchmann S, Kohl C, Treiber A.

Clin Pharmacokinet. 2016 Mar;55(3):369-80. doi: 10.1007/s40262-015-0322-y.

PMID:
26385839
16.

First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity.

Bruderer S, Hurst N, de Kanter R, Miraval T, Pfeifer T, Donazzolo Y, Dingemanse J.

Antimicrob Agents Chemother. 2015 Feb;59(2):935-42. doi: 10.1128/AAC.04125-14. Epub 2014 Nov 24.

17.

Macitentan does not interfere with hepatic bile salt transport.

Treiber A, Äänismaa P, de Kanter R, Delahaye S, Treher M, Hess P, Sidharta P.

J Pharmacol Exp Ther. 2014 Jul;350(1):130-43. doi: 10.1124/jpet.114.214106. Epub 2014 Apr 25.

18.

Novel S1P(1) receptor agonists--part 3: from thiophenes to pyridines.

Bolli MH, Abele S, Birker M, Bravo R, Bur D, de Kanter R, Kohl C, Grimont J, Hess P, Lescop C, Mathys B, Müller C, Nayler O, Rey M, Scherz M, Schmidt G, Seifert J, Steiner B, Velker J, Weller T.

J Med Chem. 2014 Jan 9;57(1):110-30. doi: 10.1021/jm4014696. Epub 2013 Dec 24.

PMID:
24367923
19.

Novel S1P(1) receptor agonists--part 2: from bicyclo[3.1.0]hexane-fused thiophenes to isobutyl substituted thiophenes.

Bolli MH, Velker J, Müller C, Mathys B, Birker M, Bravo R, Bur D, de Kanter R, Hess P, Kohl C, Lehmann D, Meyer S, Nayler O, Rey M, Scherz M, Steiner B.

J Med Chem. 2014 Jan 9;57(1):78-97. doi: 10.1021/jm401456d. Epub 2013 Dec 17.

PMID:
24345087
20.

Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold.

Ciana CL, Siegrist R, Aissaoui H, Marx L, Racine S, Meyer S, Binkert C, de Kanter R, Fischli C, Wittlin S, Boss C.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):658-62. doi: 10.1016/j.bmcl.2012.11.118. Epub 2012 Dec 11.

PMID:
23260352
21.

Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies.

de Graaf IA, Olinga P, de Jager MH, Merema MT, de Kanter R, van de Kerkhof EG, Groothuis GM.

Nat Protoc. 2010 Sep;5(9):1540-51. doi: 10.1038/nprot.2010.111. Epub 2010 Aug 19.

PMID:
20725069
22.
23.

Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction.

Martignoni M, Groothuis GM, de Kanter R.

Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):875-94. Review.

PMID:
17125407
24.

Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine.

Martignoni M, Groothuis G, de Kanter R.

Drug Metab Dispos. 2006 Jun;34(6):1047-54. Epub 2006 Mar 24.

25.

Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction.

de Graaf IA, de Kanter R, de Jager MH, Camacho R, Langenkamp E, van de Kerkhof EG, Groothuis GM.

Drug Metab Dispos. 2006 Apr;34(4):591-9. Epub 2006 Jan 13.

26.

An in vivo and in vitro comparison of CYP gene induction in mice using liver slices and quantitative RT-PCR.

Martignoni M, de Kanter R, Grossi P, Saturno G, Barbaria E, Monshouwer M.

Toxicol In Vitro. 2006 Feb;20(1):125-31. Epub 2005 Aug 10.

PMID:
16098711
27.

An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR.

Martignoni M, de Kanter R, Grossi P, Mahnke A, Saturno G, Monshouwer M.

Chem Biol Interact. 2004 Dec 30;151(1):1-11.

PMID:
15607757
28.

A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies.

de Kanter R, Tuin A, van de Kerkhof E, Martignoni M, Draaisma AL, de Jager MH, de Graaf IA, Meijer DK, Groothuis GM.

J Pharmacol Toxicol Methods. 2005 Jan-Feb;51(1):65-72.

PMID:
15596116
29.

Lack of strain-related differences in drug metabolism and efflux transporter characteristics between CD-1 and athymic nude mice.

Martignoni M, de Kanter R, Moscone A, Grossi P, Monshouwer M.

Cancer Chemother Pharmacol. 2005 Feb;55(2):129-35. Epub 2004 Sep 22.

PMID:
15592720
30.

Prediction of whole-body metabolic clearance of drugs through the combined use of slices from rat liver, lung, kidney, small intestine and colon.

De Kanter R, Monshouwer M, Draaisma AL, De Jager MH, de Graaf IA, Proost JH, Meijer DK, Groothuis GM.

Xenobiotica. 2004 Mar;34(3):229-41.

PMID:
15204696
31.

Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation.

Martignoni M, Monshouwer M, de Kanter R, Pezzetta D, Moscone A, Grossi P.

Toxicol In Vitro. 2004 Feb;18(1):121-8.

PMID:
14630070
32.

Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices.

De Kanter R, De Jager MH, Draaisma AL, Jurva JU, Olinga P, Meijer DK, Groothuis GM.

Xenobiotica. 2002 May;32(5):349-62.

PMID:
12065058
33.

[Five year survival of posterior adhesive bridges. Influence of bonding systems and tooth preparation].

Creugers NH, de Kanter RJ, Verzijden CW, van 't Hof MA.

Ned Tijdschr Tandheelkd. 1999 Jul;106(7):250-3. Dutch.

PMID:
11930370
34.

[The reproduction of the interocclusal relationship with the aid of a 'jig'].

Koers LG, de Kanter RJ.

Ned Tijdschr Tandheelkd. 1997 Oct;104(10):388-9. Dutch. No abstract available.

PMID:
11924431
35.

Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues.

de Kanter R, Monshouwer M, Meijer DK, Groothuis GM.

Curr Drug Metab. 2002 Feb;3(1):39-59. Review.

PMID:
11878310
36.

Patients' satisfaction in two long-term clinical studies on resin-bonded bridges.

Creugers NH, De Kanter RJ.

J Oral Rehabil. 2000 Jul;27(7):602-7.

PMID:
10931253
37.

A systematic review of single-tooth restorations supported by implants.

Creugers NH, Kreulen CM, Snoek PA, de Kanter RJ.

J Dent. 2000 May;28(4):209-17. Review.

PMID:
10722893
38.

Organ slices as an in vitro test system for drug metabolism in human liver, lung and kidney.

De Kanter R, Olinga P, De Jager MH, Merema MT, Meijer DK, Groothius GM.

Toxicol In Vitro. 1999 Aug-Oct;13(4-5):737-44.

PMID:
20654543
39.

Loss of sound tooth structure when replacing amalgam restorations by adhesive inlays.

Moscovich H, Creugers NH, De Kanter RJ, Roeters FJ.

Oper Dent. 1998 Nov-Dec;23(6):327-31.

PMID:
9855856
40.

In vitro milling accuracy and fit of 'natural inlays'.

Moscovich H, Von den Hoff JW, Creugers NH, De Kanter RJ.

J Dent. 1998 Jul-Aug;26(5-6):453-7.

PMID:
9699437
41.

Risk factors and multiple failures in posterior resin-bonded bridges in a 5-year multi-practice clinical trial.

Creugers NH, De Kanter RJ, Verzijden CW, Van't Hof MA.

J Dent. 1998 Jul-Aug;26(5-6):397-402.

PMID:
9699428
42.

A rapid and simple method for cryopreservation of human liver slices.

de Kanter R, Olinga P, Hof I, de Jager M, Verwillegen WA, Slooff MJ, Koster HJ, Meijer DK, Groothuis GM.

Xenobiotica. 1998 Mar;28(3):225-34.

PMID:
9574813
43.

Effect of composite basing on the resistance to bulk fracture of industrial porcelain inlays.

Moscovich H, Roeters FJ, Verdonschot N, de Kanter RJ, Creugers NH.

J Dent. 1998 Mar;26(2):183-9.

PMID:
9540317
44.

A five-year multi-practice clinical study on posterior resin-bonded bridges.

De Kanter RJ, Creugers NH, Verzijden CW, Van't Hof MA.

J Dent Res. 1998 Apr;77(4):609-14.

PMID:
9539464
45.

Concern about TMD: a comment from 'the international forum'.

De Kanter RJ.

Acta Odontol Scand. 1997 Dec;55(6):408. No abstract available.

PMID:
9477036
46.

Comparison of five incubation systems for rat liver slices using functional and viability parameters.

Olinga P, Groen K, Hof IH, De Kanter R, Koster HJ, Leeman WR, Rutten AA, Van Twillert K, Groothuis GM.

J Pharmacol Toxicol Methods. 1997 Oct;38(2):59-69.

PMID:
9403776
47.

Long-term survival data from a clinical trial on resin-bonded bridges.

Creugers NH, De Kanter RJ, van 't Hof MA.

J Dent. 1997 May-Jul;25(3-4):239-42.

PMID:
9175352
48.

Temporomandibular disorders in the medical practice.

Okeson JP, de Kanter RJ.

J Fam Pract. 1996 Oct;43(4):347-56. Review.

PMID:
8874369
49.

Prevalence in the Dutch adult population and a meta-analysis of signs and symptoms of temporomandibular disorder.

De Kanter RJ, Truin GJ, Burgersdijk RC, Van 't Hof MA, Battistuzzi PG, Kalsbeek H, Käyser AF.

J Dent Res. 1993 Nov;72(11):1509-18.

PMID:
8227702
50.

Demand and need for treatment of craniomandibular dysfunction in the Dutch adult population.

De Kanter RJ, Käyser AF, Battistuzzi PG, Truin GJ, Van 't Hof MA.

J Dent Res. 1992 Sep;71(9):1607-12. Erratum in: J Dent Res 1993 Jan;72(1):87.

PMID:
1522294

Supplemental Content

Loading ...
Support Center